{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:50:19Z","timestamp":1781585419617,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T10:36:27Z","timestamp":1657881387000},"page":"e959-e971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke"],"prefix":"10.1016","volume":"22","author":[{"given":"Anna","family":"Narezkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-8578","authenticated-orcid":false,"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-1817","authenticated-orcid":false,"given":"Shaun P.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise","family":"Hilts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.004_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.07.004_bib0002","article-title":"National Cancer Institute Surveillance, Epidemiology, and End Results Program","year":"2021","journal-title":"SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia"},{"key":"10.1016\/j.clml.2022.07.004_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.004_bib0004","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 Update on diagnosis, risk stratification and treatment","volume":"9","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.004_bib0005","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","article-title":"Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies","volume":"105","author":"Delgado","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.004_bib0006","unstructured":"GAZYVA (obinutuzumab) Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2021."},{"key":"10.1016\/j.clml.2022.07.004_bib0007","unstructured":"REVLIMID (lenalidomide) Prescribing Information. Summit, NJ: Celgene Corp.; 2021."},{"key":"10.1016\/j.clml.2022.07.004_bib0008","unstructured":"IMBRUVICA (ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2020."},{"key":"10.1016\/j.clml.2022.07.004_bib0009","unstructured":"CALQUENCE (acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP;2019."},{"key":"10.1016\/j.clml.2022.07.004_bib0010","unstructured":"VENCLEXTA (venetoclax) Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2020."},{"key":"10.1016\/j.clml.2022.07.004_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.004_bib0013","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.004_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.004_bib0016","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.004_bib0017","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.004_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clml.2022.07.004_bib0019","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2022.07.004_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","article-title":"Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation","volume":"23","author":"Sestier","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2022.07.004_bib0021","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","article-title":"Causes of death and influencing factors in patients with atrial fibrillation","volume":"129","author":"Fauchier","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2022.07.004_bib0022","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.004_bib0023","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.004_bib0024","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.clml.2022.07.004_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-140577","article-title":"Real-world outcomes of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): A systematic review and meta-analysis","volume":"136","author":"Cheung","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.004_bib0026","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data","volume":"12","author":"Isaac","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2022.07.004_bib0027","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2022.40.16_suppl.7539","article-title":"Acalabrutinib \u00b1 obinutuzumab versus obinutuzumab\u202f+\u202fchlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN","volume":"40","author":"Sharman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0028","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients","volume":"134","author":"Yazdy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.004_bib0029","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"Jul 26","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000102","article-title":"Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium","volume":"2","author":"Alonso","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clml.2022.07.004_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clml.2022.07.004_bib0032","series-title":"Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update","author":"Sanders","year":"2018"},{"key":"10.1016\/j.clml.2022.07.004_bib0033","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.amjcard.2018.10.037","article-title":"Relation of the CHA2DS2-VASc score to risk of thrombotic and embolic stroke in community-dwelling individuals without atrial fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study)","volume":"123","author":"Koene","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2022.07.004_bib0034","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijcard.2012.09.148","article-title":"Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study","volume":"168","author":"Lip","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clml.2022.07.004_bib0035","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.004_bib0036","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"Medrxiv"},{"key":"10.1016\/j.clml.2022.07.004_bib0037","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020","journal-title":"arXiv"},{"key":"10.1016\/j.clml.2022.07.004_bib0038","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.07.004_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136121","article-title":"Clinical outcomes among real-world patients with chronic lymphocytic leukemia (CLL) initiating first-line ibrutinib or chemoimmunotherapy (CIT) stratified by risk status: Results from a US retrospective chart review study","volume":"136","author":"Huang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.004_bib0040","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv. Ther"},{"issue":"15 suppl","key":"10.1016\/j.clml.2022.07.004_bib0041","doi-asserted-by":"crossref","first-page":"e19512","DOI":"10.1200\/JCO.2021.39.15_suppl.e19512","article-title":"Analyzing treatment patterns and time to the next treatment in chronic lymphocytic leukemia real-world data using automated temporal phenotyping","volume":"39","author":"Lee","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0042","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.004_bib0043","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.004_bib0044","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-134119","article-title":"A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL\/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.004_bib0046","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: Results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.004_bib0047","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","article-title":"How to manage atrial fibrillation secondary to ibrutinib","volume":"3","author":"Essa","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clml.2022.07.004_bib0048","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.004_bib0049","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.004_bib0050","first-page":"e2701","article-title":"Management of atrial fibrillation in patients on ibrutinib: a Cleveland Clinic experience","volume":"10","author":"Khalid","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.clml.2022.07.004_bib0051","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/10428194.2019.1688321","article-title":"Changing landscape of frontline therapy in chronic lymphocytic leukemia","volume":"61","author":"Bhat","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:03Z","timestamp":1761871263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002221"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}